person · Reporting owner

COATS LONNEL

Disclosed activity across 4 companies

Tapewire entity: 39692
SEC CIK: 0001612528

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970	Director · Chief Executive Officer	February 28, 2024	February 29, 2024
Relay Therapeutics, Inc.RLAY · Entity 4044	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LEXICON PHARMACEUTICALS, INC.

Report date February 28, 2024 · Filed February 29, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,098,068	Ending reported balance After 2024-02-28 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2024-02-28 · Exercise / conversion · Acquired 33,333 · Balance 947,692 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2024-02-28 · Exercise / conversion · Acquired 91,364 · Balance 1,039,056 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 3 · 2024-02-28 · Exercise / conversion · Acquired 120,383 · Balance 1,159,439 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 4 · 2024-02-28 · Tax withholding · Disposed 61,371 · Balance 1,098,068 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-28 · Exercise / conversion · Disposed 33,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	91,363	Reported balance After 2024-02-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-28 · Exercise / conversion · Disposed 91,364 · Balance 91,363 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	240,767	Reported balance After 2024-02-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-28 · Exercise / conversion · Disposed 120,383 · Balance 240,767 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

Relay Therapeutics, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08	Direct	32,947	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-07-17 transaction · row 1 1 source row Row 1 · 2025-07-17 · Disposition to issuer · Disposed 6,144 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, 2,242 shares of Common Stock held by the Reporting Person were cancelled and automatically converted into the right to receive the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.01	Direct	Reported balance After 2025-07-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-17 · Disposition to issuer · Disposed 11,818 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.53	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 10,909 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.02	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 10,909 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.77	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 4,875 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.24	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 3,188 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.13	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.64	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, 2,242 shares of Common Stock held by the Reporting Person were cancelled and automatically converted into the right to receive the Offer Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Verve Therapeutics, Inc.

Report date July 25, 2025 · Filed July 28, 2025

Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02	Direct	0	Reported balance After 2025-07-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-07-25 · Disposition to issuer · Disposed 136,139 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73	Direct	0	Reported balance After 2025-07-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-25 · Disposition to issuer · Disposed 42,200 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 19, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	3,000	$1.40	$4,194.00	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 8 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,539 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	16,000	$1.36	$21,760.00	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 7 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,539 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	3,500	$1.35	$4,725.00	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 6 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,539 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	600	$1.35	$807.00	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 5 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,039 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	6,600	$1.34	$8,844.00	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 4 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,439 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	100	$1.34	$133.50	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 3 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,839 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	10,044	$1.33	$13,358.52	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 2 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,739 Read SEC document
August 16, 2019 Filed Aug 20, 2019 21:02 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	156	$1.33	$206.70	Disclosure SEC source: 0001127602-19-027072 · form4.xml · nonDerivative · entry 1 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,695 Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:34 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $15.01	$0.00	Disclosure SEC source: 0001179110-19-009616 · edgar.xml · derivative · entry 5 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,818 Underlying: Common Stock · 10,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on February 3, 2016. This option vested with respect to 1/36th of the shares underlying the option on March 3, 2016 and as to an additional 1/36th of the shares underlying the option each month thereafter. Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:34 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,200	$81.59	$342,678.00	Disclosure SEC source: 0001179110-19-009616 · edgar.xml · nonDerivative · entry 4 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.19 to $81.94 per share. Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:34 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,098	$82.48	$255,523.04	Disclosure SEC source: 0001179110-19-009616 · edgar.xml · nonDerivative · entry 3 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.955 to $82.95 per share. Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:34 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,702	$83.57	$225,806.14	Disclosure SEC source: 0001179110-19-009616 · edgar.xml · nonDerivative · entry 2 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,298 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.97 to $83.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (3) to this Form 4. Read SEC document
August 15, 2019 Filed Aug 19, 2019 16:34 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	10,000	$15.01	$150,100.00	Disclosure SEC source: 0001179110-19-009616 · edgar.xml · nonDerivative · entry 1 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 19, 2019 Filed Jun 20, 2019 16:35 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantRestricted Stock Units · Derivative	1,312	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007981 · edgar.xml · derivative · entry 2 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. F3 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document
June 19, 2019 Filed Jun 20, 2019 16:35 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,875	$0.00 Strike: $96.77	$0.00	Disclosure SEC source: 0001179110-19-007981 · edgar.xml · derivative · entry 1 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 4,875 shares Expires 2029-06-19 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	23,513	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · derivative · entry 9 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,027 Underlying: Common Stock · 23,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F6 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	5,363	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · derivative · entry 8 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,725 Underlying: Common Stock · 5,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	8,390	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · derivative · entry 7 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,390 Underlying: Common Stock · 8,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	10,835	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · derivative · entry 6 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,835 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Tax withholdingCommon Stock	18,641	$5.51	$102,711.91	Disclosure SEC source: 0001127602-19-009259 · form4.xml · nonDerivative · entry 5 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,539 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	23,513	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · nonDerivative · entry 4 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	5,363	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · nonDerivative · entry 3 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	8,390	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · nonDerivative · entry 2 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 28, 2019 Filed Mar 1, 2019 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	10,835	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-009259 · form4.xml · nonDerivative · entry 1 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 07, 2019 Filed Feb 8, 2019 22:59 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	GrantRestricted Stock Units · Derivative	238,140	$0.00	$0.00	Disclosure SEC source: 0001127602-19-004868 · form4.xml · derivative · entry 2 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,140 Underlying: Common Stock · 238,140 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document
February 07, 2019 Filed Feb 8, 2019 22:59 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	GrantStock Option (Right to Buy) · Derivative	442,260	$0.00 Strike: $5.16	$0.00	Disclosure SEC source: 0001127602-19-004868 · form4.xml · derivative · entry 1 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,260 Underlying: Common Stock · 442,260 shares Expires 2029-02-07 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/7/2020) and vests 1/48th per month for each month of service thereafter Read SEC document
June 21, 2018 Filed Jun 25, 2018 16:57 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $69.79	$0.00	Disclosure SEC source: 0001179110-18-009004 · edgar.xml · derivative · entry 1 COATS LONNEL · CIK 0001612528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,136 Underlying: Common Stock · 7,500 shares Expires 2028-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	5,362	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-009725 · form4.xml · derivative · entry 7 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,088 Underlying: Common Stock · 5,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	8,390	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-009725 · form4.xml · derivative · entry 6 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,780 Underlying: Common Stock · 8,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionRestricted Stock Units · Derivative	10,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-009725 · form4.xml · derivative · entry 5 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,835 Underlying: Common Stock · 10,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Tax withholdingCommon Stock	9,494	$8.53	$80,983.82	Disclosure SEC source: 0001127602-18-009725 · form4.xml · nonDerivative · entry 4 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,079 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	5,362	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-009725 · form4.xml · nonDerivative · entry 3 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	8,390	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-009725 · form4.xml · nonDerivative · entry 2 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 28, 2018 Filed Mar 2, 2018 22:07 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	Exercise / conversionCommon Stock	10,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-009725 · form4.xml · nonDerivative · entry 1 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
February 08, 2018 Filed Feb 12, 2018 22:11 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	GrantStock Option (Right to Buy) · Derivative	211,610	$0.00 Strike: $9.79	$0.00	Disclosure SEC source: 0001127602-18-005199 · form4.xml · derivative · entry 2 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,610 Underlying: Common Stock · 211,610 shares Expires 2028-02-08 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/8/2019) and vests 1/48th per month for each month of service thereafter. Read SEC document
February 08, 2018 Filed Feb 12, 2018 22:11 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	GrantRestricted Stock Units · Derivative	70,540	$0.00	$0.00	Disclosure SEC source: 0001127602-18-005199 · form4.xml · derivative · entry 1 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,540 Underlying: Common Stock · 70,540 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F2 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document
November 15, 2017 Filed Nov 15, 2017 22:15 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	10,000	$9.91	$99,100.00	Disclosure SEC source: 0001127602-17-032220 · form4.xml · nonDerivative · entry 1 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,985 Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	400	$12.64	$5,054.44	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 25 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,985 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	300	$12.62	$3,786.96	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 24 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,585 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	300	$12.62	$3,784.83	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 23 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,285 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	600	$12.62	$7,569.96	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 22 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,985 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	300	$12.65	$3,793.98	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 21 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,385 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	300	$12.58	$3,772.83	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 20 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,085 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	306	$12.54	$3,836.32	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 19 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,785 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	1,200	$12.52	$15,022.80	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 18 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,479 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	100	$12.52	$1,251.50	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 17 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,279 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	400	$12.52	$5,006.48	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 16 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,179 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	194	$12.51	$2,426.94	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 15 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,779 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	149	$12.57	$1,872.36	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 14 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,585 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
September 15, 2017 Filed Sep 18, 2017 10:40 UTC	LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970	PurchaseCommon Stock	1,200	$12.58	$15,091.92	Disclosure SEC source: 0001127602-17-027540 · form4.xml · nonDerivative · entry 13 COATS LONNEL · CIK 0001612528 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,436 F1 · ownership.direct: Since the date of Mr. Coats' last ownership report, he transferred 17,782 shares of common stock to his ex-wife pursuant to a domestic relations order. Mr. Coats no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.